Profile

Christopher Hulme

Co-Director, Arizona Center for Drug Discovery | Professor, BIO5 Institute | Member of the Graduate Faculty | Professor, Pharmacology and Toxicology

Pharmacology and Toxicology

Full Page

Overview

Research

Collaboration(14)

Page 1 of 3

Grants(12)

Establishing a Pleiotropic Brain-Penetrant Small-Molecule to Impede Glioblastoma
Active·2023·$197.8K / $268.8K·
External
Principal Investigator (PI)
glioblastoma, brain-penetrant small-molecule, drug development, neurological disease, cancer treatment
DYRK1B Inhibition for Prostate Cancer
Active·2023·$0 / $153.5K·
External
Key Personnel (KP)
prostate cancer, dyrk1b inhibition, cancer treatment, molecular targeting, drug development
Establishing a Pleiotropic Brain-Penetrant Small-Molecule to Impede Glioblastoma
Active·2023·$57.5K / $60.6K·
External
Principal Investigator (PI)
glioblastoma, brain-penetrant small-molecule, drug development, neurological disease, cancer treatment
Commercialization of Selective Dyrk1a inhibitors for Down Syndrome
Active·2022·$116.7K·
External
Principal Investigator (PI)
drug development, down syndrome, enzyme inhibitors, commercialization, therapeutic intervention
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
Active·2020·$3.2M / $3.8M·
External
Principal Investigator (PI)
alzheimer's, dyrk1a, inhibition, treatment, novel

Page 1 of 3

Publications(124)

Recent

Six-Component Reactions and Beyond: The Nuts and Bolts.

2022

multicomponent reactions, organic synthesis, reaction mechanism, catalysis, chemical diversity

The Omnipresence of DYRK1A in Human Diseases

2022

genetic disorders, cellular signaling, neurological disorders, molecular biology, developmental disorders

DYRK1a antagonists rescue degeneration and behavioral deficits of in vivo models of Alzheimer’s disease and Down’s Syndrome

2022

alzheimer's disease, down's syndrome, neurodegeneration, behavioral deficits, dyrk1a antagonists

5- Trig Oxidative Radical Cyclizations of Ugi-3CR Products toward 1,4-Imidazolidinones

2021

organic synthesis, catalysis, heterocyclic compounds, radical chemistry, medicinal chemistry

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6.

2020

medicinal chemistry, drug development, biological targets, therapeutic innovation, mechanistic studies

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5

2019

medicinal chemistry, drug discovery, pharmacology, biomedical research, therapeutic innovations

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

2019

alzheimer's disease, neurodegeneration, dyrk1 inhibition, mouse model, pathology

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4

2018

medicinal chemistry, drug discovery, biomedical research, pharmacology, healthcare innovation

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

2018

influenza, antivirals, drug resistance, chemistry, pharmacology

Aza-Riley Oxidation of Ugi-Azide and Ugi-3CR Products toward Vicinal Tricarbonyl Amides: Two steMCR-Oxidation Methodology Accessing Functionalized α,β-diketoamides and α,β-diketotetrazoles.

2018

organic chemistry, chemical synthesis, oxidation reactions, amide synthesis, multicomponent reactions

People

Profile

Christopher Hulme

Collaboration(14)

Kenneth Knox

Denise Roe

Fernando Martinez

William Montfort

Stefano Guerra

Grants(12)

Establishing a Pleiotropic Brain-Penetrant Small-Molecule to Impede Glioblastoma

DYRK1B Inhibition for Prostate Cancer

Establishing a Pleiotropic Brain-Penetrant Small-Molecule to Impede Glioblastoma

Commercialization of Selective Dyrk1a inhibitors for Down Syndrome

DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease

Publications(124)

Six-Component Reactions and Beyond: The Nuts and Bolts.

The Omnipresence of DYRK1A in Human Diseases

DYRK1a antagonists rescue degeneration and behavioral deficits of in vivo models of Alzheimer’s disease and Down’s Syndrome

5- Trig Oxidative Radical Cyclizations of Ugi-3CR Products toward 1,4-Imidazolidinones

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5

Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

Aza-Riley Oxidation of Ugi-Azide and Ugi-3CR Products toward Vicinal Tricarbonyl Amides: Two steMCR-Oxidation Methodology Accessing Functionalized α,β-diketoamides and α,β-diketotetrazoles.